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A B S T R A C T
The aim of this study was to investigate the clinical usefulness of MK-467 (vatinoxan; L-659’066) in dogs
sedated for diagnostic imaging with medetomidine-butorphanol. It was hypothesised that MK-467
would alleviate bradycardia, hasten drug absorption and thus intensify the early-stage sedation. In a
prospective, randomised, blinded clinical trial, 56 client-owned dogs received one of two IM treatments:
(1) 0.5 mg/m2 medetomidine + 0.1 mg/kg butorphanol (MB, n = 29); or (2) 0.5 mg/m2 medetomidine +
0.1 mg/kg butorphanol + 10 mg/m2 MK-467 (MB-MK, n = 27). Heart rates and visual sedation scores were
recorded at intervals. Plasma drug concentrations were determined in venous samples obtained
approximately 14 min after injection. Additional sedation (50% of original dose of medetomidine IM) and/
or IM atipamezole for reversal were given when needed. The area under the sedation score-time curve for
visual analogue scale (AUCVAS30) was calculated for the first 30 min after treatment using the trapezoidal
method. Repeated ANOVA, Mann–Whitney U test and Fisher’s exact test were used for parametric, non-
parametric and dichotomous data. Heart rate was significantly higher from 10 to 40 min with MB-MK
than with MB. AUCVAS30 was significantly higher after MB-MK. More dogs treated with MB-MK required
additional sedation after 30 min, but fewer needed atipamezole for reversal compared with MB. Plasma
concentrations of both medetomidine and butorphanol were higher after MB-MK. All procedures were
successfully completed. MK-467 alleviated the bradycardia, intensified the early stage sedation and
shortened its duration in healthy dogs that received IM medetomidine-butorphanol.
© 2018 Published by Elsevier Ltd.
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The α2-adrenoceptor agonists medetomidine and dexmedeto-
midine produce reliable sedation and some degree of analgesia,
permitting minor procedures to be performed in clinical veterinary
practice (Scheinin and MacDonald,1989; Murrell and Hellebrekers,
2005). Butorphanol is a synthetic opioid that is frequently used
with medetomidine to enhance the quality of sedation in dogs
(Pypendop et al., 1996; Kuo and Keegan, 2004). However, all
α2-adrenoceptor agonists have adverse effects, mainly related to
depression of the cardiovascular system. Specifically, α2-adreno-
ceptor agonists induce vasoconstriction (Bloor et al., 1992),
followed by marked baroreflex-mediated bradycardia (Pypendop* Corresponding author.
E-mail address: ira.kallio-kujala@helsinki.fi (I.J. Kallio-Kujala).
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1090-0233/© 2018 Published by Elsevier Ltd.and Verstegen, 1998). The bradycardia is associated with
pronounced decreases in cardiac output and oxygen delivery
(Bloor et al., 1992; Pypendop and Verstegen, 1998), an outcome
that challenges the usefulness of these drugs.
Although the beneficial effects (i.e. sedation and analgesia) of
α2-adrenoceptor agonists are produced at the level of the central
nervous system (CNS), activation of peripheral α2-adrenoceptors
located within vascular smooth muscle leads to the initial
vasoconstriction and related cardiovascular effects (Clough and
Hatton,1981; Horn et al.,1982). In view of this, MK-467 (vatinoxan;
L-659’066), a peripherally acting α2-adrenoceptor antagonist
(Clineschmidt et al., 1988), has been investigated for its ability
to prevent or attenuate the negative impact of dexmedetomidine
and medetomidine in dogs (Pagel et al., 1998; Enouri et al., 2008;
Honkavaara et al., 2008; Honkavaara et al., 2011).
Only a small proportion of MK-467 crosses the blood–brain
barrier into the mammalian CNS (Clineschmidt et al., 1988). Thus,
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organs outside the blood–brain barrier. Several studies have
demonstrated that MK-467 is able to prevent cardiovascular
depression in dogs (Pagel et al., 1998; Enouri et al., 2008;
Honkavaara et al., 2008, 2011) without substantially altering the
sedation elicited by dexmedetomidine and medetomidine
(Honkavaara et al., 2008; Restitutti et al., 2011, 2017). It has also
been shown that concomitant administration of MK-467 attenu-
ates the cardiovascular effects of a medetomidine–butorphanol
combination when both are given by intramuscular (IM) injection
in the same syringe (Salla et al., 2014). Furthermore, an increase in
the absorption rate of medetomidine, when combined with
MK-467 for IM administration, has been reported (Restitutti
et al., 2017).
To date, studies on MK-467 in dogs have been performed using
laboratory beagles under controlled, experimental conditions.
Hence, our aim was to investigate the effects of MK-467 on
sedation and bradycardia expected after IM administration of
medetomidine and butorphanol in healthy dogs of various breeds
in a clinical environment. We hypothesised that MK-467, when
co-administered IM with medetomidine and butorphanol, would




After receiving approval from the National Animal Experimental Board of
Finland (approval number ESAVI/6082/04.10.07/2016, Date of approval 8th October
2016), the study was performed at the Veterinary Teaching Hospital, Faculty of
Veterinary Medicine, University of Helsinki, Finland. The target population was
client owned dogs that required sedation for non-invasive radiographic imaging.
Inclusion criteria were weight 5 kg, age from 3 months to 10 years and American
Society of Anesthesiologists (ASA) classification I and II. Exclusion criteria were
breed-related contraindication for deep sedation (e.g. brachycephalic syndrome),
systemic disease or medications affecting the CNS. Informed consent was obtained
from the owners. Most of the dogs enrolled in the study were scheduled for
radiographic imaging required by the Finnish Kennel Club Health Programme for
the screening of canine genetic diseases and defects.
Experimental design
In a randomised, complete, block design, animals were assigned to receive one
of two treatments: (1) 0.5 mg/m2 medetomidine HCl + 0.1 mg/kg butorphanol
tartrate (MB); or (2) 0.5 mg/m2 medetomidine HCl + 0.1 mg/kg butorphanol
tartrate + 10 mg/m2 MK-467 HCl (MB-MK). The body surface area was calculated
using the following formula: body surface area (m2) = 10.1  (weight in kg)2/3 102
(White and Kearney, 2014; Pypendop and Jones, 2015). The dose of medetomidine
HCl (0.5 mg/m2) was equivalent to a dose of 29.5 mg/kg for a 5 kg dog and 11.7 mg/kg
for an 80 kg dog. A solution containing 0.5 mg/mL medetomidine HCl for the MB
treatment and a solution containing 0.5 mg/mL medetomidine HCl and 10 mg/mL
MK-467 HCl (Vetcare Oy; Recipharm) was used for the MB-MK-treatment.
Butorphanol (Torpudor 10 mg/mL, Richter Pharma AG) was drawn up separately
and mixed with the solution containing medetomidine before administration. The
end volume of the injectable solution in both treatments was 0.03 to 0.07 mL/kg
(0.57 mL for a 10 kg dog), depending on the weight. Randomisation (Microsoft Office
Excel) into treatment groups was performed in blocks for breed (Retrievers,
Shepherds, Spitzs and the group ‘Other breeds’) and weight (small dogs 5–10 kg,
medium size dogs 11–30 kg and large dogs >31 kg) to ensure relatively
homogeneous populations between treatments. Treatments were administered
IM into the gluteal muscles.
Ten minutes after drug injection, a catheter was inserted in a cephalic vein
aseptically and blood was drawn into tubes containing ethylene diamine tetra-
acetic acid (EDTA) for plasma drug concentration analyses and complete blood
counts, and into a serum tube for basic serum chemistry. Blood samples obtained
later than 20 min after drug injection were excluded from the plasma drug
concentration data. The total volume harvested was <10 mL, representing no more
than 3% of the total blood volume of a 5 kg dog. Plasma was separated by
centrifugation at 2300 g for 10 min within 30 min after collection and stored at
20 C until analysis for medetomidine, butorphanol and MK-467 concentrations.
Oxygen was supplemented with a loose mask at 2–4 L/min according to the
dog’s size. Prior to treatment administration, heart rate (HR) was assessed by
auscultation, respiratory rate was assessed by observation of thoracic movements,
colour of the mucous membranes was assessed by direct observation and the levelof sedation was scored. The evaluations were repeated at 5 min after treatment and
thereafter at 10 min intervals. Rectal temperatures were measured prior to
treatment administration and at every 30 min. Dogs were passively insulated with
blankets; if the body temperature decreased <37 C, they were warmed actively by a
convective temperature management system (Bair-Hugger, 3M).
The primary investigator who assessed the sedation was blinded to the
treatment. A second investigator administered the treatments and recorded the HRs
and other clinical variables. Sedation was determined using a visual analogue scale
(VAS) from 0 to 100, where 0 represents no sedation and 100 represents the animal
in lateral recumbency, unresponsive to a loud hand clap. The ‘area under the
sedation score time’ curve for VAS was calculated for the first 30 min after
treatment (AUCVAS30) using the trapezoidal method. ‘Head down time’ was
recorded as the time when the dog had become recumbent and did not react to the
hand clap. If the level of sedation was inadequate for performing the radiographic
imaging, as judged by the blinded investigator, 50% of the initial medetomidine dose
(without butorphanol and MK-467) was administered IM. Treatment failure was
defined as insufficient sedation after the additional medetomidine.
The duration of required sedation was recorded as the time from the IM
injection until the radiographic imaging was concluded. After successful comple-
tion of the procedure, the blinded investigator administered 0.625 mg/m2
atipamezole IM (37 mg/kg for a 5 kg dog; Alzane 5 mg/mL, Laboratorios SYVA S.
A.U.) if the dog was not able to stand or walk. If the dog was not able to stand on its
own after the first dose, the same dose was re-administered 10 min later. The
evaluations were continued as described above until the animal was standing. The
owner was interviewed by telephone the following day regarding the overall
behaviour of the dog: (1) was the dog more lethargic than normal in the evening
after sedation; (2) was there anything else out of the ordinary; and (3) were there
any changes in appetite, faeces or behaviour? Owners were blinded to the treatment
until the end of the telephone call.
Analytical methods
Concentrations of medetomidine, butorphanol and MK-467 in plasma were
measured using liquid chromatography coupled with tandem mass spectrometry
(LC–MS/MS; Waters Acquity UPLC + Waters TQ-S triple quadrupole MS). After
precipitation of 100 mL plasma samples in a 96-well precipitation plate (Waters
Sirocco Waters) with 200 mL acetonitrile containing 20 ng/mL chlorpromazine as an
internal standard, the plasma supernatants were transferred to new 96-well plates
and a 50 mL aliquot was transferred to another 96-well plate and diluted 1:10 in 20%
aqueous acetonitrile prior to analysis. Diluted and undiluted samples were
analysed. Reference standards were prepared by ‘spiking’ blank dog plasma with
the analytes, producing final concentrations in the range 0.02–20,000 ng/mL. The
linear calibration ranges were fitted as 0.2–500 ng/mL for undiluted butorphanol,
0.2–2000 ng/mL for diluted medetomidine and 0.5–2000 ng/mL for undiluted MK-
467. The quality control samples were within 94–116% of the nominal concen-
trations.
Statistical analysis
A power analysis, based on mean HRs of 40 (MB) and 60 (MB-MK) beats per min
(bpm), with a standard deviation of 15 bpm, suggested that 20 dogs per group was
required with a power of 80% and α level of 0.05. The Shapiro–Wilk test was used to
evaluate the normality of data distributions. Heart and respiratory rates were
evaluated by analysis of variance (ANOVA; general linear model), where time was a
within-subject factor and treatment was a between-subject factor. A t test with the
Holm–Bonferroni post-hoc correction was used for comparisons between treat-
ments and against baseline. The independent samples t test was performed on
plasma drug concentrations and time for ‘head down’. Areas under the curve
(AUCVAS30) were compared using the Mann–Whitney U test. VAS and pale mucous
membranes were compared between the two treatments at each time point using
the Mann–Whitney U test and against baseline within each treatment using the
related samples Friedman’s two-way ANOVA by ranks. The Holm–Bonferroni
correction was used with both comparisons. The need for additional medetomidine
or atipamezole, presence of loose faeces, lethargy and decreased appetite were
compared using the two-sided Fischer’s exact test. Analyses were computed using
SPSS Statistics version 24.0 for Windows (IBM). P values <0.05 were considered to
be statistically significant.
Results
The MB group contained 29 dogs and the MB-MK group
contained 27 dogs (Table 1). None of the dogs had pertinent
alterations in haematology or serum chemistry considered to be
consequential to the investigated outcomes. All the procedures
were completed successfully and no treatment failures occurred in
either group. Side effects, considered to be minor, are reported in
Table 2.
Table 1
Characteristics of 56 dogs undergoing sedation with either MB (n = 29) or MB-MK
(n = 27) for radiography.
MB n MB-MK n
Weight
(kg)a
18.6 (6.3–42.0) 24.6 (8.8–71.0)
Age (years)a 2.3 (1.1–8.8) 2.9 (1.1–9.4)
Sex Male 12 Male 9
Female 17 Female 18
Breed German shepherd 4 German shepherd 5
Border collie 3 Flat coat retriever 2
Giant schnauzer 3 Lapphund 2
Golden retriever 2 Lapponian herder 2
Lapphund 2 Pyrenean mastiff 2
Lapponian herder 2 Whippet 2
Mudi 2 American Staffordshire bull
terrier
1
Mixed breed 2 Australian shepherd 1
Bohemian shepherd 1 Bassett hound 1
Cairn terrier 1 Bedlington terrier 1
Cirneco delletna 1 Border collie 1
Cocker spaniel 1 Cairn terrier 1
Flat coated retriever 1 Cocker spaniel 1
Miniature
schnauzer
1 Entlebucher sennenhund 1
Podenco 1 Giant schnauzer 1
Schweizer laufhund 1 Golden retriever 1
Whippet 1 Mixed breed 1
Norwegian elkhound 1
MB, 0.5 mg/m2 medetomidine + 0.1 mg/kg butorphanol; MB-MK, 0.5 mg/m2 mede-
tomidine + 10 mg/m2 MK–467 + 0.1 mg/kg butorphanol.
The group size of a breed for each treatment is expressed as the number of
individuals of that breed.
a Median and range in curved brackets. No significant differences were detected
between groups in weight, age or sex.
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however, HR was significantly higher in the MB-MK group than
in the MB group (Fig. 1). HRs were reported until 40 min; at that
time point, two dogs were missing from each group, representing
the end of the procedure for one dog in each group and the
requirement for additional sedation in one dog in each group. The
lowest HRs detected after additional treatment with medetomi-
dine were 28 bpm in the MB group (n = 1) and 34 bpm in the
MB-MK group (n = 7). One dog in the MB group had an increased HR
after drug administration (up to 148 bpm); this was considered to
be an outlier the HR data for this dog were excluded from Fig. 1 and
from the statistical analyses.Table 2
Results for 56 dogs undergoing sedation with either MB (n = 29) or MB-MK (n = 27) for
MB 
Head down (s)a 297.5  74.3 
Pale mucous membranesb 10 
Additional medetomidineb (mina) 1 (30) 
Atipamezole administrationb 26 
Duration of required sedationc (mina) 66  14.5 (30–94) 
Lethargyb 26 
Loose faecesb 7 
Decrease in appetiteb 2 
Blood sample analysedb 23 
Blood sampling time (min)c,d 13 (11–15) 
Medetomidine (ng/mLa) 9  3 
Butorphanol (ng/mLa) 16  7 
MK-467 (ng/mLa) 
MB, 0.5 mg/m2 medetomidine + 0.1 mg/kg butorphanol; MB-MK, 0.5 mg/m2 medetomid
Lethargy, loose faeces and decrease in appetite reported by owners.
One dog in both groups received additional medetomidine and one dog in both group
a Mean  standard deviation.
b Number of dogs.
c Range in curved brackets.
d Median.VAS and AUCVAS30 are shown in Table 3. In the MB-MK group,
more dogs required additional sedation after 30 min than in the MB
group. In addition, fewer dogs in the MB-MK group required
administration of atipamezole (Table 2). Respiratory rates
decreased after both treatments, with no significant difference
between groups. The lowest respiratory rates were detected at
20–30 min, with medians of 8 and 10 breaths per min in the MB-
MK and MB groups, respectively. None of the dogs had a rectal
temperature below 37 C. Due to technical problems there were
many missing blood pressure readings (data not analysed nor
shown).
Plasma concentrations of both medetomidine and butorphanol
were significantly higher in the MB-MK group in samples collected
11–18 min after drug injection (Table 2). ‘Head down’ time, mucous
membrane colour, duration of required sedation, lethargy, loose
faeces, decrease in appetite, number of blood samples analysed
and sampling time are shown in Table 2.
Discussion
The findings of this study, using a population of healthy dogs in
a clinical setting, indicate that administration of MK-467 IM
concomitantly with medetomidine and butorphanol alleviates
medetomidine-related bradycardia. Profound bradycardia
(approximately 40 bpm) was detected in dogs treated with
medetomidine and butorphanol (MB group). The HR was also
low in dogs treated with medetomidine, butorphanol and MK-467
(MB-MK group; mean HR approximately 60 bpm). However,
similar or even lower HRs have been detected in untreated,
healthy sleeping dogs; nightly HRs 60–70 bpm have been
reported in beagle dogs (Nolan et al., 2004; Honkavaara et al.,
2008). Moreover, in healthy, adult, pet dogs, minimum HRs of
17–46 bpm have been detected on ambulatory electrocardiography
(Hall et al., 1991) and, in a more recent study, the mean of the
minimum HRs was also <50 bpm (Cruz Aleixo et al., 2017). In our
study, HR was significantly lower than baseline in the MB-MK
group, which suggests that MK-467 did not override the central
component of the bradycardic action of α2-agonists (Savola, 1986),
although it was presumed to have been able to alleviate the
baroreflex-mediated bradycardia caused by peripheral α2-adre-
noceptor activation.
The present results should not be over-interpreted, since we did
not show that cardiac output or oxygen delivery were improved by
the addition of MK-467. However, in experimental canine studies, radiography.
MB-MK P value
241.4  77.8 0.012
3 0.058
7 (53  10) 0.023
12 <0.001






14  4 <0.001
35  15 <0.001
607  204
ine + 10 mg/m2 MK–467 + 0.1 mg/kg butorphanol.
s received additional atipamezole.
Fig. 1. Heart rates until 40 min after injection for dogs that did not receive additional medetomidine or atipamezole. *Significant difference between treatments.
Table 3
Visual analogue sedation score (0–100) and the area under the sedation score time
curve (AUC) for visual analogue scale (VAS) for the first 30 min (AUCVAS30).
Time point (min) MB MB-MK
0 0 (0–0) n = 29 0 (0–0) n = 27
5 58 (9–86) n = 28 64* (21–100) n = 27*
10 96 (31–100) n = 27* 100 (51–100) n = 27*
20 100 (82–100) n = 28* 100 (78–100) n = 27*
30 100 (83–100) n = 28* 100 (71–100) n = 27*
40 100 (90–100) n = 26* 100 (14–100) n = 25*
AUCVAS30 2445 (1855–2585)† 2555 (1868–2750)†
MB, 0.5 mg/m2 medetomidine + 0.1 mg/kg butorphanol; MB-MK, 0.5 mg/m2 mede-
tomidine + 10 mg/m2 MK–467 + 0.1 mg/kg butorphanol.
Data are reported as median (range).
* Significant difference from baseline.
† Significant difference between treatments.
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improvement of cardiac output (Honkavaara et al., 2011; Salla et al.,
2014). The lack of blood pressure data in our study is a major
limitation; blood pressure was monitored non-invasively and
blood pressure measurements could not be carried out systemati-
cally at the prescribed same time points, nor using the same artery,
because the clinical priority was to avoid excessive interference
with the radiological exams. Therefore, we did not consider the
data to be reliable and further studies using clinical cases are
needed.
The onset of sedation appeared to be faster in the MB-MK group
and, initially, was deeper than in the MB group. The ‘head-down’
time was significantly shorter in the MB-MK group and we
detected a deeper overall sedation during the first 30 min.
Subsequently, dogs in the MB-MK group were more alert than
dogs in the MB group, since more additional medetomidine and
less atipamezole were required. Thus, the use of MK-467 can be
considered advantageous, especially if short, intense, sedation is
required. If additional medetomidine was needed, medetomidine
alone was given to dogs in both groups, since no studies have been
performed on the effects of repeated doses of MK-467 in sedated
dogs. Since the need for additional sedation arose after a mean of
52 min in dogs in the MB-MK group, the duration and magnitude of
the sedative effect of medetomidine and butorphanol combined
with MK-467 could provide sufficient sedation to complete a minor
non-invasive procedure. The quality and level of sedation induced
by medetomidine in our study probably were improved by
butorphanol, independent of MK-467, in accordance with that
reported previously (Pypendop et al., 1996; Ko et al., 2000).Conversely, the effects of MK-467 on the plasma concentration
profile of medetomidine and butorphanol apparently also affected
the depth of sedation.
The interactions between α2-adrenoceptors and their antago-
nists start at the site of the extravascular injection; MK-467
enhances the IM absorption of medetomidine, probably by
preventing local vasoconstriction caused by medetomidine
(Restitutti et al., 2017) and it also appears to affect the absorption
of other co-administered sedatives (Kallio-Kujala et al., 2017). In
our study, plasma medetomidine and butorphanol concentrations
were significantly higher in the MB-MK group than in the MB
group. The plasma sample was collected approximately 14 min
after the injection, when we expected to detect a clear difference
between the treatments based on our previous findings (Kallio-
Kujala et al., 2017; Restitutti et al., 2017). Furthermore, Restitutti
et al. (2017) reported that the time-concentration curves of
dexmedetomidine intersected at approximately 30 min; the
plasma concentration of medetomidine was higher in the presence
of MK-467 before the 30 min time point, whereas later it was
higher in dogs that had received medetomidine alone IM. These
effects of MK-467 on the plasma concentration profiles of
medetomidine and butorphanol probably explain both the deeper
initial sedation observed in the MB-MK group and the later lighter
plane of sedation in the MB-MK group when compared with the
MB group.
The most frequent side effects after sedation in both groups
were lethargy and loose faeces during the evening after the
examination. All dogs that had loose faeces had received one or
both of the α2-adrenoceptor antagonists MK-467 and/or atipame-
zole. Atipamezole restores intestinal motility after α2-adrenocep-
tor agonist-induced sedation and induces defaecation in dogs
(Maugeri et al., 1994). Moreover, frequent defaecation after
administration of MK-467 has been reported in horses (DeVries
et al., 2016). Therefore instead of giving atipamezole in one single
dose, we administered two equal (0.625 mg/m2) smaller doses if
needed, to reduce the risk of intestinal hypermotility, especially in
the presence of MK-467, but still to have the desired effect of
reversing the sedation. Honkavaara et al. (2008) administered
atipamezole 50 mg/kg (1.25 mg/m2 for a 16 kg dog) to reverse
sedation induced by IV dexmedetomidine and MK-467.
Conclusions
MK-467 alleviates the bradycardia induced by medetomidine in
dogs in a clinical setting, and provides reliable sedation for short
26 I.J. Kallio-Kujala et al. / The Veterinary Journal 240 (2018) 22–26term clinical procedures, such as diagnostic imaging, when it is
combined with IM medetomidine and butorphanol in healthy
dogs. In addition, MK-467 increases the early stage plasma
concentration of both medetomidine and butorphanol when
administrated IM in the same syringe and results in deeper initial
sedation with shorter duration.
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